Last reviewed · How we verify
RAPA-201 Autologous T cells
At a glance
| Generic name | RAPA-201 Autologous T cells |
|---|---|
| Also known as | RAPA-201 cells |
| Sponsor | Rapa Therapeutics LLC |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Phase 2b of RAPA-201 Cell Therapy in Post-PD-(L)-1 Melanoma (PHASE2)
- RAPA-201 T Cell Therapy for Relapsed, Refractory Multiple Myeloma (PHASE2)
- RAPA-201 Therapy of Solid Tumors (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- RAPA-201 Autologous T cells CI brief — competitive landscape report
- RAPA-201 Autologous T cells updates RSS · CI watch RSS
- Rapa Therapeutics LLC portfolio CI